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Abstract
Purpose: To study the time course (onset, time and duration of  maximal cycloplegia, and the full duration) of  cycloplegic action 
of  1% Cyclopentolate – 1% Tropicamide.
Methods: Seventy-seven students, aged 15-24 years were purposively sampled from the University of  Cape Coast and Cape 
Coast Technical Institute. Subjective near addition (ADD) determination and pupil diameter measurement before and after a 
drop of  the test agent (1% Cyclopentolate – 1% Tropicamide combination in the right eye) and the control (1% Cyclopentolate 
in the left eye) were performed. Measurements of  subjective near ADD and pupil diameter were made after the initial reading at 
5 minutes interval for the first hour and every 30 minutes for the next 7 hours for each participant. Time of  onset, time of  peak 
cycloplegia, duration of  peak cycloplegia and duration of  total cycloplegic effect was indirectly determined.
Results: 1% Cyclopentolate – 1% Tropicamide combination had rapid onset of  cycloplegia (5-10 minutes), shorter time of  
maximal cycloplegia (55 versus 90 minutes), and recovery (7 versus ≥ 8hours) in the majority (79.2%) of  subjects.
Conclusion: Cyclopentolate –Tropicamide combination was comparable to Cyclopentolate in depth of  cycloplegia produced, 
and clinically superior to 1% Cyclopentolate in rapidity of  cycloplegic onset, time of  maximal cycloplegia and recovery from 
cycloplegia.
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Accurate determination of  refractive status requires sup-
pression of  the accommodative response of  the patient1. 
However, fogging with plus lenses is not always adequate, 
especially for the diagnosis of  refractive conditions such 
as latent hyperopia2. Pharmacologic agents, known as cy-
cloplegic agents, are used when such conditions are pres-
ent or are suspected.
Cycloplegia refers to the pharmacological paralysis of  the 
ciliary muscles, and it results primarily in inhibition of  
accommodation2,3. Cycloplegic agents prevent the action 
of  acetylcholine at muscarinic receptor sites. Based on 
their mechanism of  action, cycloplegics are referred to 
as anti-cholinergics, anti-muscarinics or parasympatholy-
tic agents4,5. Muscarinic receptors are widely distributed 
throughout the human body, and immunoprecipitation 
studies have shown that all five muscarinic receptor sub-
types are present in the human eye6, especially in the iris 
and ciliary body. Instillation of  a cycloplegic agent results 
in inhibition of  accommodation and also mydriasis (due 
to paralysis of  the pupillae sphincter muscle). However, 
certain cycloplegics have been reported to have produced 
mydriasis but very little accommodative suppression7,8. 
Mydriasis also occurs without accompanying cycloplegia 
when a sympathomimetic agent is used. Thus, mydria-
sis is not always evidence of  accompanying cycloplegia. 
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Because of  the different time courses of  mydriasis and 
cycloplegia, pupil size is a poor indicator of  the cyclople-
gic effect4,9.
Cycloplegic agents are indispensable in the diagnosis of  
latent hyperopia, pain relief  from  ciliary spasm, break-
ing or preventing irido-lenticular or irido-corneal adhe-
sion, as well as penalization (or occlusion therapy) in eye 
care3,10-12. Cycloplegics also stabilize the blood-aqueous 
barrier and thus prevent further protein leakage (flares) 
into the anterior chamber13 in cases of  uveitis.  Though 
all the 5 muscarinic receptor sub-types are located in the 
eye, they are also widely distributed in other parts of  the 
body. For this reason, anti-muscarinics are not only used 
in eye care6,12.
Generally, cycloplegics can cause local (ocular) and sys-
temic side effects. Local effects include elevated intraoc-
ular pressure, blurred vision, photophobia, stinging sen-
sation and injected bulbar conjunctiva5,8,13. Systemic side 
effects include dry mouth and skin, tachycardia, skin rash, 
psychotic reactions, behavioural disturbances, etc. An-
gle-closure glaucoma, after using an antimuscarinic agent, 
is a possible occurrence in susceptible persons but its in-
cidence is however very rare3,5. Most adverse effects of  
antimuscarinics are associated with atropine use. They in-
clude hyperthermia, central nervous system (CNS) effects 
of  hallucinations, restlessness, ataxia, and even death3,8,12.
The ideal cycloplegic agent is one that has rapid onset, 
suppresses much accommodation, wears off  faster, and 
is associated with no or minimal side effects. In response 
to finding an ideal cycloplegic agent, Cyclopentolate – 
Tropicamide combination has been reported by several 
researchers as having superior cycloplegic effect to the 
current agent of  choice (Cyclopentolate) and comparable 
cycloplegic effect to Atropine, the gold standard14,15. The 
time course of  action of  Atropine, Cyclopentolate, and 
all other cycloplegics and mydriatic agents are well docu-
mented3,8,16.
Although Cyclopentolate – Tropicamide combination 
has been recommended as first line agent for cycloplegic 
examination, little or no information on the time course 
(onset, time to attain maximal cycloplegia, duration of  
maximal cycloplegia and total duration) of  this combi-
nation is available for any racial population. This study 
focused on the time course of  1% Cyclopentolate – 1% 
Tropicamide combination among young African students 
in the Cape Coast metropolis of  Ghana.
Materials and methods
Study design and subject selection
The study was conducted as an experimental study, to de-
termine the time course of  cycloplegic action of  the test 
agent, i.e. 1% Cyclopentolate – 1% Tropicamide combi-
nation. Students were purposively recruited, and taken 
through an eye examination at the Department of  Op-
tometry clinic, University of  Cape Coast. The examina-
tion involved;
•  History taking to determine presence of  any ocular or 
medical condition in which the use of  a cycloplegic agent 
is contraindicated.
•   Digital sphygmomanometry to determine subjects’ nor-
mal blood pressure (Arm Digital Blood Pressure Monitor 
HZ-5915, Shanghai Huazhe Int. Co., Ltd, China).
•   Distance and near visual acuity assessment (with Snel-
len and Grafton Optical near chart) for 6/6 and N.5 vi-
sion in each eye.
• Ocular health assessment including measuring normal 
intraocular pressure, assessing open or wide anterior 
chamber with Van Herrick’s technique, and the absence 
of  ocular disease using a slit lamp biomicroscope (YZ 
5F1 Slit lamp with motorized table and applanation to-
nometer, Weihai Dingxin Optical Co., Ltd, China).
Subjects were excluded if  they failed any of  the criteria 
above.
One hundred and ten students were approached but after 
the examination, 77 students, comprising 27 females and 
50 males aged 15 – 24 years, participated in the study to 
the end. Ten were excluded from the study after the initial 
examination as they did not meet the criteria indicated 
above. Another 4 did not turn up for the experimental 
study and 9 withdrew at various stages of  the study.
 
Data collection procedure
In order to minimize the effect of  inter-subject variations 
on the results, the control (1 % Cyclopentolate) and test 
agents (1 % Cyclopentolate – 1% Tropicamide) were in-
stilled in the left and right eye of  the same subject respec-
tively. Prospective participants were purposively sampled 
from University of  Cape Coast and Cape Coast Technical 
Institute.
Prior to instillation of  the drops, habitual pupil diameter 
of  participants’ eyes were measured (with a pupillometer), 
and least plus lens (subjective near ADD) through which 
N.5 optotypes on the Grafton Opticals near chart could 
be recognized and read were determined and recorded.
One drop of  Drug A (1% Cyclopentolate – 1% Tropi-
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camide combination) and Drug B (1% Cyclopentolate) 
were instilled  in the lower fornix of  each participant’s 
anaesthetized right and left eye respectively, 2.5 minutes 
apart. This difference in time of  instillation was to en-
sure that within the 5 minute period for each round of  
measurements, 2.5 minutes would be spent on each eye. 
After instillation, punctal occlusion was done in order to 
prevent or minimize the amount of  drug that could get 
into systemic circulation.
Drug A was prepared by mixing an equal volume of  1% 
Cyclopentolate and 1% Tropicamide (Ashford Labora-
tories Ltd, China Macau). After instillation, the variables 
(pupil diameter and least near ADD) were measured ev-
ery 5 minutes for 1 hour, and every 30 minutes for the 
next 7 hours. Data was collected from February 2016 to 
May 2016.
 
Thin layer chromatography (TLC) of  drug agents
In order to ascertain whether or not a new product was 
formed when equal volumes of  1% Cyclopentolate and 
1% Tropicamide are mixed, thin layer chromatography 
was performed. The procedure is described below;
A straight line was drawn with a pencil along the breadth 
of  a clean 10 cm x 3.6 cm preparative chromatographic 
plate (stationary phase) 1cm from the bottom edge of  
the plate. A drop of  1% Cyclopentolate, 1% Tropicamide 
and a mixture of  the two compounds in 1:1 ratio were 
spotted on 1cm interval points along the straight line on 
the chromatographic plate, using clean capillary tubes. 
The spotted points were labelled; C for 1% Cyclopento-
late, M for 1% Cyclopentolate – 1% Tropicamide mixture 
and T for 1% Tropicamide. Ethyl acetate (solvent system 
or the mobile phase) was poured into a clean dry jar so 
that it was 0.7cm deep from the bottom of  the jar. The 
edge of  the chromatographic plate, nearest to the spotted 
side was placed into the jar. After the paper was orient-
ed to vertically lean against the wall of  the jar, the jar 
was covered, and the setup was left undisturbed for a few 
minutes, during which the solvent rose to about ¾ of  the 
length of  the plate. The plate was then removed, dried 
and placed inside an iodine chamber for identification of  
compounds. The procedure was carried out at normal 
room temperature. The spotted points on the paper were 
then circled with a pencil, and measurements of  distance 
moved by sample and solvent front were taken and their 
Rf  values calculated17.
Determination of  pH
pH of  the drug agents used was measured using a pH 
meter (Denver instrument GmbH, Germany). Each 





The study was approved by the University of  Cape Coast 
Institutional Review Board (Reference number: UC-
CIRB/CHAS/2015/065) and permission was sought 
from authorities of  Cape Coast Technical Institute. Par-
ticipants aged 18 years and older signed a written in-
formed consent form which outlined the purpose of  the 
study, procedures and its associated risks. Verbal consent 
and parental consent were obtained from participants be-
low 18 years. Anonymity as well as confidentiality of  par-
ticipants was ensured. Participation in the study was vol-
untary, and participants could withdraw at any stage from 
the study. No incentives were provided to participants 
aside the free eye examination. The study was conducted 
in accordance with the tenets of  the Helsinki declaration 
regarding the use of  human subjects in research.
 
Statistical analysis
Data was entered into and analyzed with Microsoft Excel 
2013 and IBM SPSS Statistics 21 (The IBM Co., Chica-
go IL, USA.). Mean values of  pupil diameter and least 
plus lens were calculated with Microsoft Excel 2013, and 
represented on graphs and tables. IBM SPSS Statistics 21 
software was used for testing association; One sample T 
test was used for testing difference between the mean val-
ues for Drug A and Drug B, whereas Independent T test 
was used for testing difference between sub-groups’ mean 
values (i.e. mean least plus lens values between males and 
females, and also between teenagers and young adults).
Results
Demographic characteristics
A total of  77 healthy students, 50 (65%) of  which were 
males, and 27 (35%) were females participated in the 
study. Mean age of  participants was 19.5 ± 2.48 years, 
with the youngest and oldest subject being 15 years and 
24 years respectively. Two age groups were formed; 15-
19  years group (teenage) and 20-24 years group (young 
adult), with the latter having the higher number of  partic-
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ipants (43 subjects, 55.8%) in the study. The young adult 
group comprised 37 males and 6 females, with 12 males 
and 22 females in the teenage group.
Mydriasis
The mean habitual pupil diameter of  the right and left 
eyes of  all the subjects were 3.14 mm and 3.13 mm re-
spectively (Fig. 1). A slight increase in pupil diameter was 
observed 5 minutes after instillation of  1% Cyclopento-
late – 1% Tropicamide. However, the change of  0.32 mm 
that was measured is less than the least clinically-mea-
surable change in pupil diameter of  0.5 mm. The first 
clinically-measurable change, i.e. at 3.65 mm pupil diam-
eter, occurred 5-10 min after instillation, making this the 
clinically-significant onset of  mydriasis of  Drug A (1% 
Cyclopentolate – 1% Tropicamide). Clinically-significant 
onset of  mydriasis of  1% Cyclopentolate(at 3.63 mm pu-
pil diameter) occurred 15 min after instillation drops.
Significant differences were found in mydriatic action of  
Drug A and Drug B (p<0.001; One sample t test). Pro-
gression (increase) of  mydriasis was observed to be rath-
er slow with Drug B (1% Cyclopentolate). Peak mydriasis 
of  1% Cyclopentolate was 6.28 mm, and it occurred at 
270 minutes. However, Drug A (1% Cyclopentolate – 
1% Tropicamide) obtained 3.5 hours quicker and 1.1mm 
broader peak mydriasis (7.29 mm, at 60 min; Fig. 1).
Independent t test was run to find significant differenc-
es in mydriasis between males and females, and also be-
tween teenagers and young adults. There was no signifi-
cant difference in mydriasis between males and females 
with either Drug A or B (p=0.45 for Drug A, p=0.54 
for Drug B), and neither was there any significant differ-
ence between teenagers and the young adults (p=0.93 for 
Drug A, p=0.32 for Drug B).
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Cycloplegia
Prior to instillation, all participants had near visual acuity 
of  N5 through plano lens. Clinically-measurable onset of  
cycloplegic action (requiring at least 0.25D plus lens), for 
both drugs, occurred 5 min after instillation (Fig. 2).
The summit of  the least plus lens, (LPL) curve indicates 
peak cycloplegic activity. With 1% Cyclopentolate – 1% 
Tropicamide, LPL values increased and reached maximal 
cycloplegia at 55 min (1.85D). Taking into account that 
the refractive lens power equivalent for 1.85D lies be-
tween 1.75D and 2.00D, clinical equivalent of  maximal 
cycloplegia is observed to have persisted for 55min (from 
35-90 min, Fig. 2), and cycloplegic activity ended at 420 
min (Fig. 2).
However, with 1% Cyclopentolate, maximal cycloplegia 
occurred at 90 min (1.96D ≈ 2.00D) and persisted for 
at least 30 minutes (from a time somewhere between 60 
and 90 min to 120 min; Fig. 2). Cycloplegic activity of  1% 
Cyclopentolate ended at 480 min.
At their peaks, 1% Cyclopentolate achieved 0.11D more 
cycloplegia than 1% Cyclopentolate – 1% Tropicamide.
Majority of  participants (61, 79.2%) recovered unaided 
reading ability (reading through plano lens) about 1 hour 
quicker in the eye instilled with 1% Cyclopentolate – 1% 
Tropicamide (Fig. 2). Generally, differences in the cyclo-
plegic action of  Drug A and Drug B were found to be 
significant (p<0.001; One sample t test).
Table 1: Summary of Findings
FINDING DRUG A DRUG B
ONSET OF MYDRIASIS 5-10min 15min
PEAK MYDRIASIS 7.29mm 6.28mm
TIME OF PEAK MYDRIASIS 60min 270min
ONSET OF CYCLOPLEGIA 5min 5min
TIME OF PEAK CYCLOPLEGIA 55min 90min
DURATION OF PEAK 
CYCLOPLEGIA
55min (35-90min) At least 30 minutes 
(90-120min)
DURATION OF TOTAL 
CYCLOPLEGIC EFFECT
7hr > 8hr
Drug A: 1% Cyclopentolate – 1% Tropicamide Drug B: 1% Cyclopentolate
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Independent t test was run to find significant differenc-
es in cycloplegic action between males and females, and 
also between teenagers and young adults. With 1% Cy-
clopentolate – 1% Tropicamide, there were no significant 
difference in least plus lens between males and females 
(p=0.08), and between the teenagers and young adults 
(p=0.06). With 1% Cyclopentolate, there were significant 
differences in gender (p=0.02) and age (p=0.03) in least 
plus lens values. Females had lower values and about 30 
mins shorter duration of  total cycloplegic effect (Fig. 3). 
Subjects in the 15-19 years category also had lower values 
(of  about 0.50D difference in clinical equivalent between 
them and the 20-24yrs category) from 15 min to 90min, 
and about 30 min longer duration than the young adult 
group (Fig. 4).
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Major variations
In 2 teenage females, mydriasis occurred without accom-
panying cycloplegia in the eye instilled with the combi-
nation drug and also in the eye instilled with 1% Cyclo-
pentolate. In 1 young female adult, mydriasis occurred 
without accompanying cycloplegia in the eye instilled 
with 1% Cyclopentolate. A similar event occurred in a 
young male adult, howbeit in the eye instilled with the 
combination drug. In 1 young male adult, the eye instilled 
with 1% Cyclopentolate recovered unaided reading ability 
faster than the eye instilled with 1% Cyclopentolate – 1% 
Tropicamide. Finally, 10 subjects (made up of  males and 
females belonging to the teenage and young adult group) 
recovered unaided reading ability in both eyes after 8 hrs.
 
Thin layer Chromatography (TLC) result
After the TLC procedure, 1% Tropicamide and 1% Cy-
clopentolate had one spot each with Rf  values of  0.67 
and 0.37 respectively (Figure 5). The mixture of  1% Cy-
clopentolate and 1% Tropicamide (1:1) had 2 spots and 
their Rf  values were 0.37 and 0.67 respectively (Figure 5, 
marked as m). This compared to Rf  values of  the pure 
drug agents showed same Rf  values to that of  the com-
bined agent, indicating that the combination had resulted 
in no new chemical agent.
The pH recordings were as follows;
•      Cyclopentolate: 3.34 ± 0.03
•      Tropicamide:4.56 ± 0.05
•      Cyclopentolate – Tropicamide combination: 4.44 ± 
0.04
 
Side and adverse effects
Expected side effects, such as stinging on instillation and 
photophobia were reported by all participants. However, 
there was no report of  any other adverse effect during or 
after the study.
Discussion
Both the test and control drug agents had quick onset of  
mydriasis, but that of  1% Cyclopentolate – 1% Tropi-
camide was at least 5 minutes quicker. Tropicamide exerts 
an antagonistic effect on muscarinic receptors M4, M1 
and M2, whereas Cyclopentolate antagonizes muscarinic 
receptor M1. Thus when combined, Tropicamide exerts 
an added effect of  inhibiting M4 and M2, as Tropicamide 
and Cyclopentolate competitively inhibit M1 action18. 
This may be the reason why onset of  mydriasis (5-10min) 
and duration of  the combined drug (6-7 hrs) are similar to 
Fig. 5: TLC plate showing spots
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that of  Tropicamide as their pHs were highly comparable 
and could have been better tolerated than the Cyclopen-
tolate upon instillation suggesting a superior penetration 
of  the ocular tissues3,16. Quicker onset of  mydriasis in it-
self  does not have much clinical implication, unlike rate 
of  mydriatic progression (which affects time for maximal 
pupil dilation) and maximal pupil diameter. This is be-
cause dilated fundus examinations are performed on fully 
dilated pupils. 1% Cyclopentolate – 1% Tropicamide was 
observed to progress in mydriasis quicker, and attained 
peak mydrasis 3.5 hours before 1% Cyclopentolate did. 
With respect to dilated fundus exams, this means that all 
things being equal, patients administered with the com-
bination drug would be examined 3.5 hours before those 
administered with 1% Cyclopentolate. This would ensure 
a significant and much appreciated decrease in waiting 
time for most patients and clinicians. In addition, there is 
a clinical advantage of  being able to examine more of  the 
vitreo-retinal space with 1% Cyclopentolate – 1% Tropi-
camide, during dilated intraocular assessment, since it was 
found to produce greater mydriasis (of  1mm more) than 
1% Cyclopentolate.
Depth of  cycloplegia was not the focus of  this study. 
However, at their peaks, 1% Cyclopentolate achieved 
0.11D more cycloplegia than 1% Cyclopentolate – 1% 
Tropicamide. The clinical equivalent for 0.11D (i.e. 0.00D) 
meant that 1% Cyclopentolate was not significantly supe-
rior to the combination drug in terms of  the amount of  
cycloplegia that could be produced. The clinical implica-
tion is that, peak cycloplegia produced by 1% Cyclopen-
tolate – 1%Tropicamide combination and 1% Cyclopen-
tolate are comparable. Furthermore, considering clinical 
equivalent values, the greatest possible difference in peak 
cycloplegia was 0.25D. The capability, of  one drug agent 
to produce a maximum of  0.25D peak cycloplegia in ex-
cess of  that produced by another drug agent, would not 
be sufficient to recommend that drug over the other.
Peak mydriasis did not always coincide with peak cyclo-
plegia. This has an important clinical implication; that 
maximal mydriasis should not be used as the only check 
for peak cycloplegia. Also in a few subjects, mydriasis oc-
curred without clinically-significant cycloplegia. Possible 
reasons for this include tight squeezing of  the lids imme-
diately after instillation, (which resulted in loss of  signif-
icant amount of  drug) and/or increased reflex tears (as 
a result of  stinging sensation) which resulted in loss of  
significant amount of  drug and/or reduced concentra-
tion of  drug. In both situations, the amount of  drug that 
is absorbed would only be sufficient to cause mydriasis, 
but not cycloplegia. There are reports of  certain concen-
trations of  cycloplegics being effective for only mydriasis 
but not cycloplegia7,8. This may also be the explanation 
for the unusual finding of  one young male subject recov-
ering unaided reading ability faster with 1% Cyclopento-
late. In any case, this study confirms a researcher’s finding 
that pupil size is a poor indicator of  cycloplegic effect9.
Ten participants (13%) comprising males and females 
across all the studied age groups regained unaided read-
ing ability after 8 hrs. This was observed in eyes instilled 
with the combination drug, and also in eyes instilled with 
the single drug. Together with those who achieved mydri-
asis without accompanying cycloplegia, they form outli-
ers of  the study. An inherent anatomical or physiological 
phenomenon is probably the best explanation for such 
occurrences, since conditions for the study were equal for 
all subjects.
It is known that when melanin binds any drug, a lesser 
concentration of  the unbound drug may be available to 
cause the pharmacologic effect in the ocular tissues. The 
pharmacological effect can be sustained over a relatively 
longer period of  time by the slow release of  the drug 
from melanin, if  the binding is reversible. It is known that 
there are differences in melanin pigmentation between 
males and females, with females generally being lighter 
in skin pigmentation than males19. Thus if  males are rela-
tively much pigmented than females, it is understandable 
that a slower release of  the drug (and consequently a lon-
ger duration of  total cycloplegic effect) would be seen. It 
was therefore not surprising when females generally re-
covered unaided reading ability about 30 min faster with 
1% Cyclopentolate. However, this cannot be considered 
the only explanation for this occurrence, because this was 
only seen with 1% Cyclopentolate, and not with the com-
bination drug.
It has been reported that prior application of  topical anes-
thesia can shorten the time to full cycloplegia,20 however, 
such influence would have masked the actual peak times 
in this comparative study. Several studies on cycloplegia 
did not administer topical anesthesia prior to instillation 
of  cycloplegics7,14.
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Conclusion
Based on the findings of  this study, it is our conclusion 
that the mixed agent provides a quicker method of  cyclo-
plegia, has an appreciable window of  peak activity and 
wears off  quicker, while offering as deep a cycloplegia as 
Cyclopentolate,  and should be adopted for routine clin-
ical use as it has the advantage of  reducing waiting time. 
However further studies should be conducted into the 
adverse effect of  its use.
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